Guidance
Update information
December 2023: We clarified our recommendations on oral isotretinoin treatment in line with the 2023 MHRA advice on the introduction of new safety measures following the October 2023 report of the Commission on Human Medicines Isotretinoin Implementation Advisory Expert Working Group. These recommendations are marked [2023].
We have also made reference to nationally accredited GPs with an Extended Role (GPwER) working within a consultant dermatologist-agreed pathway throughout the guideline, and defined this role in 'terms used in this guideline'. We also updated the definition of consultant dermatologist-led team.